DAIICHI SANKYO, INC. for DAIICHI SANKYO INC
A later version of this report replaces this one, so LegiList's totals use the current version instead. This page shows this version exactly as filed.
Versions of this report
Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.
| Filing | Filed | Amount | Counted |
|---|---|---|---|
| 2nd Quarter - Report (this page) | Jul 19, 2024 | $240,000 | Replaced |
| 2nd Quarter - Amendment | Aug 15, 2024 | $250,000 | Yes |
What was lobbied
One issue area, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
Discussions regarding H.R.5539, the ORPHAN Cures Act Discussions related to H.R.4534 - the Women and Lung Cancer Research and Preventive Services Act Discussions related to H.R.5391 - the Protecting Patient Access to Cancer and Complex Therapies Act 340B reform generally as well as HR8574 - the 340B ACCESS Act
Foreign entity interest: To the degree that public policies, either laws or regulations, commercially impact Daiichi Sankyo, Inc. so too, Daiichi Sankyo Co., LTD, the parent company, will likewise be impacted.
| Lobbyist | Covered position, as disclosed |
|---|---|
| AARON BILL | — |
| AMANDA PEZALLA | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.